Gemtuzumab Ozogamicin Maintenance
GO maintenance was associated with preserved neutrophil and platelet counts without prolonged high-grade cytopenias across dose cohorts. GO maintenance dose escalation tested 0.5, 1.0, and 2.0 mg/m2 with a 28-day dose-limiting toxicity per…
1 sources - 6 claims
GO maintenance was associated with preserved neutrophil and platelet counts without prolonged high-grade cytopenias across dose cohorts. GO maintenance dose escalation tested 0.5, 1.0, and 2.0 mg/m2 with a 28-day dose-limiting toxicity period. The recommended phase 2 GO maintenance dose was 2 mg/m2. The trial tested GO maintenance once every 28 days for up to eight cycles after remission and hematopoietic recovery assessment. No dose-limiting toxicities occurred during GO maintenance dose escalation. Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate approved for selected AML indications but limited after transplant by cytopenias.